Table 3: Compare the mean of NCV in treated patients with topiramate by type of nerves.
Type of nerves |
Drugs |
Mean |
P - value |
Median |
topiramate in baseline |
52.3 |
0.003
|
Control |
58.7 |
||
Median |
topiramate in baseline |
52.3 |
0.053
|
topiramate six month late |
52.4 |
||
Ulnar |
topiramate in baseline |
50.2 |
0.0024
|
Control |
50.8 |
||
Ulnar |
topiramate in baseline |
50.2 |
0.061
|
topiramate six month late |
50.1 |
||
Sural |
topiramate in Baseline |
46.7 |
0.003
|
Control |
50.6 |
||
Sural |
topiramate in baseline |
46.7 |
0.298
|
topiramate six month late |
46.2 |
||
Peroneal |
topiramate in baseline |
43.8 |
0.0051
|
Control |
46.4 |
||
Peroneal |
topiramate in baseline |
43.8 |
0.13 |
topiramate six month late |
43.02 |